BTK and myeloid sarcoma: BTK inhibitors are promising potential therapies for MS, and possibly for non-active SPMS, due to their ability to disrupt B cell maturation without depleting all B cells [52], and due to their ability impact myeloid cell activation and function [6, 20, 24, 33].